Key result
The polypill is an emerging treatment alternative for the secondary prevention of cardiovascular disease.
Why the study?
Does a polypill improve outcomes in patients requiring secondary prevention of cardiovascular disease?
Does a polypill improve outcomes in patients requiring secondary prevention of cardiovascular disease?
The polypill is discussed as an emerging treatment alternative for secondary prevention of cardiovascular disease.
Answers are grounded in this paper and cite their sources.
Polypill merits prospective outcome trials in secondary prevention; leaves open superiority versus optimized individual therapy.
Cardiovascular disease (CVD), defined as ischaemic heart disease, stroke and CHF, ranks as the major cause of death and a major cause of disability in the developed world. In addition, CVD engender...
No takes yet. Share an insight, caveat, or question.
Hedner et al. (2016) studied this question. The polypill is an emerging treatment alternative for the secondary prevention of cardiovascular disease.
Synapse has enriched 10 related papers. Consider them for comparative context: